LCM
RIGL icon

Laurion Capital Management’s Rigel Pharmaceuticals RIGL Stock Holding History

Laurion Capital Management’s Portfolio RIGL Stock Details RIGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-328,440
Closed -$9.82M – 663
2022
Q1 		$9.82M Buy
328,440
+30,000
+10% +$812K 0.12% 116
2021
Q4 		$7.91M Buy
298,440
+185,940
+165% +$5.61M 0.08% 152
2021
Q3 		$4.08M Buy
+112,500
New +$4.43M 0.02% 368

Other funds holding RIGL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Laurion Capital Management's RIGL Position: Q2 2022 in Review

Laurion Capital Management sold out of Rigel Pharmaceuticals (RIGL) in Q2 2022, closing a stake of 328,440 shares — an estimated $9.82M sold.

Laurion Capital Management first reported a position in RIGL in Q3 2021 and held it in 3 quarters. The position peaked at $9.82M in Q1 2022. 135 funds tracked by Wall St. Rank hold RIGL as of Q2 2022.

  • Laurion Capital Management reported no remaining Rigel Pharmaceuticals position as of Q2 2022 after selling out during the quarter.
  • Laurion Capital Management sold 328,440 Rigel Pharmaceuticals shares in Q2 2022, an estimated $9.82M.
  • Laurion Capital Management first reported a position in Rigel Pharmaceuticals in Q3 2021 and held it in 3 quarters.
  • Laurion Capital Management's Rigel Pharmaceuticals position peaked at $9.82M in Q1 2022.
  • 135 funds tracked by Wall St. Rank held Rigel Pharmaceuticals as of Q2 2022.

Based on Laurion Capital Management's 13F filing for Q2 2022, filed 15 Aug 2022.